Technical Analysis for ESLA - Estrella Immunopharma, Inc.

Grade Last Price % Change Price Change
F 0.73 -9.24% -0.07
ESLA closed down 9.24 percent on Friday, November 1, 2024, on 5 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -9.24%
Doji - Bullish? Reversal -9.24%
New 52 Week Low Weakness -9.24%
Wide Bands Range Expansion -9.24%
Lower Bollinger Band Touch Weakness -9.24%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 19 hours ago
Possible Inside Day about 19 hours ago
Down 3% about 21 hours ago
Up 5% about 21 hours ago
Up 3% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Estrella Immunopharma, Inc. Description

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMISĀ® T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. To accomplish this mission, Estrella's lead product candidate, EB103, utilizes Eureka's ARTEMISĀ® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka's ARTEMISĀ® technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. Estrella is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus ("CF33-CD19t"), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors using a "mark and kill" strategy.


Classification

Sector: Financial Services
Industry: Shell Companies
Keywords: Cancer Solid Tumors Immune System Blood Cancers CD19 Oncolytic Virus Preclinical Stage Biopharmaceutical Cd22

Is ESLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.23
52 Week Low 0.63
Average Volume 159,758
200-Day Moving Average 1.12
50-Day Moving Average 1.00
20-Day Moving Average 0.86
10-Day Moving Average 0.84
Average True Range 0.13
RSI (14) 34.64
ADX 14.0
+DI 14.37
-DI 23.89
Chandelier Exit (Long, 3 ATRs) 0.85
Chandelier Exit (Short, 3 ATRs) 1.02
Upper Bollinger Bands 1.00
Lower Bollinger Band 0.72
Percent B (%b) 0.02
BandWidth 33.04
MACD Line -0.06
MACD Signal Line -0.06
MACD Histogram -0.0019
Fundamentals Value
Market Cap 25.56 Million
Num Shares 35.2 Million
EPS -0.20
Price-to-Earnings (P/E) Ratio -3.63
Price-to-Sales 0.00
Price-to-Book 4.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.92
Resistance 3 (R3) 0.94 0.89 0.88
Resistance 2 (R2) 0.89 0.85 0.88 0.87
Resistance 1 (R1) 0.81 0.82 0.79 0.79 0.86
Pivot Point 0.77 0.77 0.76 0.76 0.77
Support 1 (S1) 0.68 0.72 0.66 0.66 0.59
Support 2 (S2) 0.64 0.69 0.63 0.58
Support 3 (S3) 0.56 0.64 0.57
Support 4 (S4) 0.54